welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
UK patients gain early access to Duchenne drug
UK patients can gain access to Santhera’s as-yet unapproved Duchenne muscular dystrophy drug via an early access scheme.
The Medicines and Healthcare products Regulatory Agency granted Raxone (idebenone) a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).
As a result of the decision, patients aged 10 and above with respiratory function decline, who are not taking gluticorticoids, will be able to get access to Raxone ahead of formal approval by the European Medicines Agency.
rareRelated
-
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyIn Duchenne muscular dystrophy (DMD), pr...
-
Santhera’s Raxone® receives first positive EAMS scientific opinion from UK’s MHRA in Duchenne muscular ...The aim of the EAMS is to provide patien...
-
Santhera PharmaceuticalsSanthera Pharmaceuticals (SIX: SANN) is ...
-
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)The aim of this Phase III study was to a...
-
Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)The purpose of the study is to assess th...
-
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
-
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...